Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGLEC7 | Q9Y286 | 1/20 | 0.37 |
| ▸ | CD22 | P20273 | 13/20 | 0.35 |
| ▸ | MAG | P20916 | 1/20 | 0.33 |
| ▸ | NEU2 | Q9Y3R4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29326804 | 1.00 | SIGLEC7 (0.37) | SIGLEC7CD22MAGNEU2 | |
| SCHEMBL29727764 | 1.00 | SIGLEC7 (0.37) | SIGLEC7CD22MAGNEU2 | |
| SCHEMBL29334798 | 0.89 | CD22 (0.49) | CD22MAG | |
| SCHEMBL29727770 | 0.89 | CD22 (0.49) | CD22MAG | |
| SCHEMBL29335065 | 0.89 | CD22 (0.49) | CD22MAG | |
| SCHEMBL24630005 | 0.89 | SIGLEC7 (0.44) | SIGLEC7CD22MAG | |
| SCHEMBL29326848 | 0.89 | SIGLEC7 (0.44) | SIGLEC7CD22MAG | |
| SCHEMBL29727743 | 0.89 | SIGLEC7 (0.44) | SIGLEC7CD22MAG | |
| SCHEMBL24630000 | 0.89 | SIGLEC7 (0.44) | SIGLEC7CD22MAG | |
| SCHEMBL29727731 | 0.89 | CD22 (0.37) | SIGLEC7CD22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238422-A1 | Hypoimmunogenic Biotherapeutics | ADAXION THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240238422-A1 | Hypoimmunogenic Biotherapeutics | ADAXION THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238422-A1 | Hypoimmunogenic Biotherapeutics | FCGR3B, CD47, IL2 | SIGLEC7 59/4885CD22 18/4885MAG 321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.